打开APP

什么情绪急救势在必行

我们在感冒发痛时会去看医生。但为什么我们在经历类似心理伤痛时不去就医呢?盖温驰说我们此时大都独自疗伤。但这不是唯一出路。他有力的论证了为何我们应该像对待身体一样照料我们的情绪和心理健康。

2015-11-06 课时:18分钟

我为什么要制造米粒大小的机器人

通过研究蚂蚁大小的昆虫的移动方式,Sarah Bergbreiter和她的团队制造的机器人小得不可思议,看起来就像机械化的爬虫……然后他们为机器人添加了动力引擎。演讲中,微型机器人研究进展会令你瞠目结舌,此外,你还会了解这些小机器人未来的三种用途。

2015-11-06 课时:7分钟

我战胜了癌症,但那并不代表什么

当被诊断出患了癌症时黛布拉·贾维斯已经在一家医院做了将近30年的牧师了。作为一名患者她学到了不少。在这个诙谐、大胆的演讲中,她解释了“癌症幸存者”的身份标识是如何让人们感到静止的。她希望我们在给自己成长和进步的空间的同时,定义自己最困难的历经,而不是被它们定义。

2015-11-10 课时:17分钟

气候问题的现状——我们能为之做些什么

我们如何解决气候变化这一全球性问题 —— 一个巨大到任何一个国家都无法单独解决的问题。经济学家尼古拉斯·斯特恩在2014年联合国气候峰会上提出了一个方案,展示了世界上所有的国家如何共同合作,解决气候问题。这是对于合作的高瞻远瞩,全世界的受益将远不止避免灾难。他不断探索:我们如何利用这个危机,为每个人创造更好的生活?

2015-11-11 课时:17分钟

什么是局灶型先天性高胰岛素血症

Part 2 of our Spotlight on diabetes and hyperinsulinism video series.

2015-11-20 课时:3分钟

什么是先天性高胰岛素血症

This a series of great resources that put a spotlight on diabetes and hyperinsulinism.

2015-11-20 课时:5分钟

什么导致了食物昏迷?

在吃了一顿丰盛的饭菜之后,没有什么小睡一会更好的了,但你知道引起这种感觉的原因吗?

2015-11-27 课时:4分钟

什么女性服药会有更严重的副作用

对过去近百年,允许上市的药品都只在男性病人身上进行试验,导致女性用药时面临剂量不当和不容许的副作用。女性和男性生理不同的重要性,最近才被考虑进医学研究领域。急诊医生Alyson McGregor研究这些差异,并在这场精彩的演讲中讨论了男性如何成为医学研究模式的历史,以及如何藉由了解两性的差异,促成对两性更有效的治疗方法。

2015-12-01 课时:16分钟

什么基因治疗能成为消灭HIV的合理工具 - David Baltimore P2

本视频由科普中国和生物医学大讲堂出品

David Baltimore (Caltech) Part 2: Why Gene Therapy Might be a Reasonable Tool for Attacking HIV

Lecture Overview:
In this set of lectures, I describe the threat facing the world from the human immunodeficiency virus (HIV) and a bold proposal on how we might meet the challenge of eliminating this disease by engineering the immune system.

In part 1, I provide a broad introduction to viruses, describing their basic properties and my own history of studying the replication of RNA viruses which led to the discovery of reverse transcriptase. I also illustrate the distinguishing features of equilibrium viruses (e.g. the common cold) that have adapted to co-exist with their host and non-equilibrium viruses (e.g. HIV) that have recently jumped from another species, are not adapted to the new host, and which can lead to disastrous outcomes (e.g. loss of immune function with potential lethality in the case of HIV).

In part 2, I describe the growing health problem that is facing the world with the spread of HIV and the limitations of current drug therapies and vaccine strategies. We need new ideas for tackling this problem. Here and in the next segment, I describe bold strategies of using gene therapy to conquer HIV, The approach that I describe in this segment involves gene therapy to produce short hairpin RNAs (siRNA) that target the destruction of a critical co-receptor of HIV, which the viruses that needs to infect cells. I discuss initial proof-of-principle experiments that suggest this approach might be feasible and the next steps needed to develop this idea into a real therapy.

In this last segment, I describe another gene therapy strategy for HIV in which we propose to develop antibody-like proteins that can be expressed by a patient's B cells and will target the HIV virus for destruction. To achieve this objective, hematopoietic (blood) stem cells must to be targeted with the gene, which will ultimately develop into B cells that express the therapeutic molecule. The ultimate goal is to produce a life-long supply of anti-HIV neutralizing antibodies. In this lecture, I describe the molecular methods underlying this strategy and a development path from proof-of-principle studies in mouse to safe trials in humans. This project receives funding from the Bill and Melinda Gates Foundation.

Speaker Bio: After serving as President of the California Institute of Technology for nine years, in 2006 David Baltimore was appointed President Emeritus and the Robert Andrews Millikan Professor of Biology. Born in New York City, he received his B.A. in Chemistry from Swarthmore College in 1960 and a Ph.D. in 1964 from Rockefeller University, where he returned to serve as President from 1990-91 and faculty member until 1994.

For almost 30 years, Baltimore was a faculty member at Massachusetts Institute of Technology. While his early work was on poliovirus, in 1970 he identified the enzyme reverse transcriptase in tumor virus particles, thus providing strong evidence for a process of RNA to DNA conversion, the existence of which had been hypothesized some years earlier. Baltimore and Howard Temin (with Renato Dulbecco, for related research) shared the 1975 Nobel Prize in Physiology or Medicine for their discovery, which provided the key to understanding the life-cycle of HIV. In the following years, he has contributed widely to the understanding of cancer, AIDS and the molecular basis of the immune response. His present research focuses on control of inflammatory and immune responses as well as on the use of gene therapy methods to treat HIV and cancer in a program called "Engineering Immunity".

Baltimore played an important role in creating a consensus on national science policy regarding recombinant DNA research. He served as founding director of the Whitehead Institute for Biomedical Research at MIT from 1982 until 1990. He co-chaired the 1986 National Academy of Sciences committee on a National Strategy for AIDS and was appointed in 1996 to head the National Institutes of Health AIDS Vaccine Research Committee.

In addition to receiving the Nobel Prize, Baltimore's numerous honors include the 1999 National Medal of Science, election to the National Academy of Sciences in 1974, the Royal Society of London, and the French Academy of Sciences. For 2007/8, he is President of the AAAS. He has published more than 600 peer-reviewed articles.

2015-12-14 课时:31分钟

进化,为什么它重要

Isn't evolution about the past? "No!" says Miller, evolution is an ongoing process that explains many questions in modern cell biology. By not teaching evolution in school, Miller worries that a generation will grow up not trusting science or the scientific method.

2016-02-23 课时:14分钟